Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | FASN | P49327 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14686745 | 0.81 | GAA (0.58) | PDK2CRBNGAAMAPK1MAPT | |
| SCHEMBL30313698 | 0.80 | MAPT (0.44) | CRBNGAAMAPTALDH1A1CYP3A4 | |
| SCHEMBL5297499 | 0.80 | MAPT (0.44) | CRBNGAAMAPTALDH1A1CYP3A4 | |
| SCHEMBL16423721 | 0.80 | MAPT (0.53) | GAAMAPTALDH1A1CYP3A4ESR2 | |
| SCHEMBL5509526 | 0.77 | CHRNB2 (0.49) | MAPTALDH1A1KDM4E | |
| SCHEMBL28120191 | 0.76 | GAA (0.52) | PDK2GAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5513636 | 0.76 | HSP90AA1 (0.50) | MAPTALDH1A1CYP3A4KDM4ESLC6A2 | |
| SCHEMBL21116031 | 0.75 | CAMKK2 (0.39) | CRBNGAAMAPTALDH1A1CYP3A4 | |
| SCHEMBL9220646 | 0.75 | PTGDR2 (0.50) | PDK2GAAFASN | |
| SCHEMBL23981527 | 0.74 | CAMKK2 (0.41) | CRBNGAAMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2004-12-30 | — | — | US | claimed |
| US-20030176510-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2003-09-18 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2001-11-01 | — | — | US | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| US-5914350-A | TREATING PARKINSON*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | claimed |
| EP-0819113-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | claimed |
| US-5659082-A | Nitro- and aminobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | claimed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | claimed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-5659082-A | Nitro- and aminobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658953-A | Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5643965-A | TREATMENT OF DOPAMINE ASSOCIATED NERVOUS SYSTEM DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PDK2 1638/4885CRBN 970/4885GAA 1186/4885 |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | PDK2 823/4885CRBN 1813/4885GAA 12/4885 |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | PDK2 823/4885CRBN 1813/4885GAA 12/4885 |
| US-20030176510-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | PDK2 823/4885CRBN 1813/4885GAA 12/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PDK2 1751/4885CRBN 964/4885GAA 1269/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | PDK2 1691/4885CRBN 1000/4885GAA 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.